Wolfe Research analyst Andy Chen initiated coverage of Oruka Therapeutics (ORKA) with an Outperform rating. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on ORKA: Oruka Therapeutics doses first participants in Phase 1 trial of ORKA-001 Oruka Therapeutics to be added to Nasdaq Biotechnology Index Disclaimer & DisclosureReport an Issue
